Bulletin
Investor Alert

New York Markets Close in:

Aug. 10, 2020, 2:15 p.m. EDT

Acute Lymphocytic Leukemia Market, Size, Share, Trends, Epidemiology Forecast till 2030

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Aug 10, 2020 (AB Digital via COMTEX) -- Acute Lymphocytic Leukemia (ALL) is a type of cancer that affects the blood and bone marrow. It starts from young white blood cells called lymphocytes in the bone marrow; mainly characterized by an overproduction of immature white blood cells, called lymphoblasts or leukemic blasts.

Acute Lymphocytic Leukemia Epidemiology Segmentation

  • Total Incident Cases of Leukemia

  • Total Incident Cases of ALL

  • Total Incident Cases of ALL Segmented by Age and Gender

  • Total Subtype-specific Cases of ALL

  • Total Genetic Mutation-specific Cases of ALL

  • Total Treated Cases of ALL

Acute Lymphocytic Leukemia Epidemiology

  • The total incident cases of ALL in the 7MM in 2017 was 10,341

  • ALL is more frequent in males compare to females.

  • The total incident cases of ALL in 2017:-

  • The United States - 5,816

  • Germany - 942

  • France - 857

  • Spain - 414

  • Japan – 872

  • The Age-Specific Incident Cases was the most in age-group

Acute Lymphocytic Leukemia Market

Acute Lymphocytic Leukemia market size in the 7MM in 2017 was USD 1,246 million

Acute Lymphocytic Leukemia Market Drivers

  • Increasing Focus Towards the Development of Targeted Therapies

  • Rising Occurrence of ALL

  • Improvement in the Diagnosis and Awareness

  • Competitive Landscape

Acute Lymphocytic Leukemia Market Barriers

  • Financial Impact

  • Generic Erosion

  • High Rate of Chemo resistance Development

Acute Lymphocytic Leukemia Emerging Therapies

  1. Imbruvica (Ibrutinib): Pharmacyclics (an AbbVie Company)

  2. Jakafi (ruxolitinib): Incyte Corporation/Novartis

  3. Motixafortide (BL-8040): BioLine Rx

  4. TC-110: TCR2 Therapeutics

  5. Lisocabtagene Maraleucel (JCAR017): Bristol-Myers Squibb

  6. TBI-1501: Takara Bio/Otsuka Pharmaceuticals

  7. UCART19: Servier/Allogene

  8. Venetoclax: AbbVie and Roche

  9. NiCord (omidubicel): Gamida Cell Ltd.

  10. Eliquis (apixaban): Bristol-Myers Squibb|Pfizer

  11. Isatuximab: Sanofi

  12. JZP-458 (recombinant Erwinia asparaginase): Jazz Pharmaceuticals

  13. Vyxeos (Daunorubicin and Cytarabine for Injection): Jazz Pharmaceuticals

  14. Daratumumab: Janssen Research & Development

  15. ProTmune: Fate Therapeutics

  16. MB-CART19.1: MiltenyiBiotec B.V. & Co. KG

  17. BPX-501 T Cells (rivogenlecleucel; iC9-CAR19 cells): Bellicum Pharmaceuticals

  18. PBCAR0191: Precision BioSciences/Servier

  19. AUTO1: Autolus Limited

  20. KTE-X19: Gilead Sciences

Request for sample pages


Table of contents

1. Key Insights

2. Executive Summary of Acute lymphocytic leukemia (ALL)

3. Competitive Intelligence Analysis for Acute lymphocytic leukemia (ALL)

4. Acute lymphocytic leukemia (ALL): Market Overview at a Glance

4.1. Acute lymphocytic leukemia (ALL) Total Market Share (%) Distribution in 2017

4.2. Acute lymphocytic leukemia (ALL) Total Market Share (%) Distribution in 2030

5. Acute lymphocytic leukemia (ALL): Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Acute lymphocytic leukemia (ALL) Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.